Skip to content

Randomized clinical trial of 2-staged hybrid coronary revascularization versus percutaneous coronary interventions for multivessel coronary artery disease

Randomized clinical trial of 2-staged hybrid coronary revascularization versus percutaneous coronary interventions for multivessel coronary artery disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059374
Enrollment
Unknown
Registered
2022-04-28
Start date
2022-04-15
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multivessel coronary artery disease

Interventions

Intervention group:2-staged hybrid coronary revascularization
Control group:Percutaneous coronary intervention

Sponsors

Liaocheng City Heart Disease Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age >=18 years; 2. Clinical indication for coronary revascularization: (1) Two-vessel disease with LAD and/or three-vessel disease with SYNTAX score 1.5 mm ) to require revascularization, it is regarded as a two-vessel disease; (2) If there is no LAD, the diagonal branch replaces the function of the LAD, and the diagonal branch is regarded as an anterior Descending treatment; 3. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Left main disease, single branch disease, double branch disease without LAD; 2. Prior PCI and/or intrastent restenosis; 3. Patients with any form of cardiac surgery and severe pleural adhesion in the past; 4. Acute myocardial infarction, preoperative cardiogenic shock, hemodynamic instability; 5. Fresh coronary thrombosis; 6. The LAD has severe muscle bridge and complicated coronary artery anatomy, so it is unsuitable for CABG or PCI without LAD. 7. Chronic occlusion of LAD or >=2 other coronary Ctos capable of revascularization; 8. Other cardiac surgery (including but not limited to valvular surgery, aortic resection, and left ventricular aneurysm resection) is planned during hospitalization; 9. Acute heart failure within 30 days, EF 12 months; 11. Severe lung disease, unable to tolerate single lung ventilation; 12. Severe obesity (BMI > 40); 13. Patients who cannot be evaluated after 1 year and cannot be followed up within 1 year at the discretion of the investigator; 14. Mental abnormality can not cooperate; Pregnant women.

Design outcomes

Primary

MeasureTime frame
Major adverse cardiac and cerebrovascular event;

Secondary

MeasureTime frame
Overall or individual incidence of major unconscionable cerebrovascular events (MACCE);Recurrent angina pectoris after surgery;Postoperative arrhythmia;Patency rate of left internal mammary artery and drug-eluting stents at 1 year;5-year survival rate;

Countries

China

Contacts

Public ContactDapeng Yu

Liaocheng City Heart Disease Hospital

deyudp@163.com+86 15863565173

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026